Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Medtronic
AstraZeneca
Moodys
Novartis
Accenture
Healthtrust
Covington
Fish and Richardson

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,968,973

« Back to Dashboard

Which drugs does patent 5,968,973 protect, and when does it expire?

Patent 5,968,973 protects VEREGEN and is included in one NDA.

This patent has thirteen patent family members in nine countries.
Summary for Patent: 5,968,973
Title: Method for treating hyperplasia
Abstract:A method for a treatment of hyperplasia caused by papilloma virus, such as for treating Condyloma acuminata which comprises administering tea catechin. Tea catechins do not involve the risk of side-effects and may be easily applied to or inserted in the infected area by the patients themselves.
Inventor(s): Cheng; Shu Jun (Beijing, CN), Wang; De Chang (Beijing, CN), Hara; Yukihiko (Fujieda, JP)
Assignee: Cancer Institute (Hospital), Chinese Academy of Medical Sciences (Beijing, CN) Mitsui Norin Co., Ltd. (Tokyo, JP)
Application Number:09/056,378
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 5,968,973

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medigene Ag VEREGEN sinecatechins OINTMENT;TOPICAL 021902-001 Oct 31, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF GENITAL WARTS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,968,973

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-321195Nov 18, 1996

Non-Orange Book US Patents Family Members for Patent 5,968,973

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,795,911 Composition for treating Condyloma acuminata ➤ Subscribe
6,197,808 Methods for treating hyperplasia ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,968,973

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 288266 ➤ Subscribe
Australia 4443897 ➤ Subscribe
Australia 716120 ➤ Subscribe
Canada 2221370 ➤ Subscribe
China 1086290 ➤ Subscribe
China 1185947 ➤ Subscribe
Germany 122009000072 ➤ Subscribe
Germany 69732402 ➤ Subscribe
European Patent Office 0842660 ➤ Subscribe C300581 Netherlands ➤ Subscribe
European Patent Office 0842660 ➤ Subscribe C00842660/01 Switzerland ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Fuji
Citi
QuintilesIMS
Chinese Patent Office
McKesson
Boehringer Ingelheim
Teva
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot